We evaluated clinical response, normalization of inflammatory markers, angiographic
stabilization (primary outcomes), relapses and adverse events (secondary outcomes) in …

Treatment of refractory Takayasu arteritis (TA) remains an unresolved clinical issue. Patients
usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC …

Background Although high-dose glucocorticoids are effective in suppressing active
inflammation of Takayasu arteritis (TAK), many patients experience relapse during tapering …

Takayasu arteritis (TAK) is a rare disease characterized by inflammation of large blood
vessels, which results in vascular stenosis, occlusion, and aneurysm formation. The …

Aim To assess outcome of 10 'difficult to treat'patients with Takayasu arteritis (TA) treated
with tocilizumab. Methods Records of 10 patients with TA who received at least six infusions …

Takayasu arteritis (TA) is a challenging large vessel vasculitis to treat. Distinguishing
disease activity from vascular damage is difficult, often relying on clinician judgement aided …

Objectives. We analysed a large cohort of patients with Takayasu arteritis, seeking robust
clinical evidence for prolonged responses to tumour necrosis factor-α (TNF-α) and …

Objectives To evaluate effectiveness and safety of infliximab dose escalation in Takayasu
arteritis (TAK) patients. To identify factors associated with refractoriness to standard-dose …

Takayasu arteritis is a rare large vessel vasculitis which has traditionally been treated with
high-dose steroids. There have been a small number of publications where biological …

Background/purpose The aim of this study is to analyze the efficacy and tolerance of
tocilizumab in patients with Takayasu arteritis (TA). Methods We retrospectively studied …